engineered T cells expressing tumor-restricted IL-12 (Outpace Bio/Lyell Immunopharma)

N/A

Report date: 2025/06/11 11:12:05

Base Information

Drug Nameengineered T cells expressing tumor-restricted IL-12 (Outpace Bio/Lyell Immunopharma)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionInterleukin-12 receptor stimulantsImmunostimulantsT lymphocytes stimulants
TargetsInterleukin-12 receptor
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOutpace Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesOutpace Bio IncLyell Immunopharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A